Blocking CB1 Receptors Produced Antidepressant Effects Through the Opioid System
A CB1 cannabinoid receptor blocker showed antidepressant-like effects in stressed mice, and these effects were mediated through the opioid system, revealing a connection between cannabinoid and opioid pathways in depression.
Quick Facts
What This Study Found
Mice subjected to foot-shock stress showed increased immobility in standard depression tests (forced swimming test and tail suspension test), modeling depressive behavior. The CB1 receptor inverse agonist AM-251 reversed this stress-induced depression-like behavior.
The key finding was that the opioid system appears to mediate this antidepressant effect. When researchers gave a low dose of the opioid blocker naltrexone alongside AM-251, the antidepressant effect was enhanced, meaning less AM-251 was needed. Conversely, a low dose of morphine blocked AM-251's antidepressant effect entirely.
None of the drug combinations affected general locomotor activity, confirming the effects were specific to depression-like behavior rather than general changes in movement.
Key Numbers
AM-251 at 0.5 mg/kg reversed stress-induced immobility. Co-administration with sub-effective naltrexone reduced the effective AM-251 dose to 0.1 mg/kg. Sub-effective morphine completely blocked AM-251's antidepressant effect at 0.5 mg/kg.
How They Did This
Male mice were subjected to intermittent foot-shock stress for 30 minutes, then tested in the forced swimming test and tail suspension test. Researchers tested AM-251 alone and in combination with naltrexone (opioid antagonist) or morphine (opioid agonist). Locomotor activity was measured separately to rule out general motor effects.
Why This Research Matters
This study reveals a previously unknown interaction between the cannabinoid and opioid systems in stress-related depression. The finding that blocking CB1 receptors produces antidepressant effects through opioid signaling suggests these two major neurotransmitter systems are more interconnected in mood regulation than previously recognized.
The Bigger Picture
Both the endocannabinoid and opioid systems are involved in mood regulation, pain processing, and reward. This study provides a mechanistic link between them in the context of stress-induced depression, which could inform development of novel treatments targeting both systems.
What This Study Doesn't Tell Us
This was a mouse study using acute stress and acute drug treatment. Depression in humans is a chronic condition with complex causes that cannot be fully captured by rodent tests. AM-251 is a research tool compound, not a clinical drug. The results may not translate directly to human depression.
Questions This Raises
- ?Would this cannabinoid-opioid interaction hold in chronic depression models?
- ?Could low-dose opioid antagonists enhance the mood effects of cannabinoid modulation in humans?
- ?Does endocannabinoid tone influence the antidepressant effects of opioid-targeted medications?
Trust & Context
- Key Stat:
- Low-dose opioid blocker enhanced the antidepressant effect of CB1 blockade by 5-fold (0.5 mg/kg reduced to 0.1 mg/kg).
- Evidence Grade:
- Preliminary evidence from an animal study. The mechanistic interaction is clearly demonstrated in mice but has not been tested in human depression.
- Study Age:
- Published in 2016. The cannabinoid-opioid interaction in mood disorders remains an active area of preclinical research.
- Original Title:
- Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice.
- Published In:
- Clinical and experimental pharmacology & physiology, 43(2), 203-12 (2016)
- Authors:
- Ostadhadi, Sattar(2), Haj-Mirzaian, Arya(2), Nikoui, Vahid, Kordjazy, Nastaran, Dehpour, Ahmad-Reza
- Database ID:
- RTHC-01238
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does blocking cannabinoid receptors treat depression?
In this mouse model, blocking CB1 receptors reversed stress-induced depression-like behavior. However, previous human trials of CB1 blockers (like rimonabant) were abandoned due to psychiatric side effects including depression, so the picture is complex.
How are the cannabinoid and opioid systems connected?
Both systems modulate mood, pain, and reward through overlapping brain circuits. This study shows that the antidepressant effect of CB1 blockade requires intact opioid signaling, suggesting the two systems interact directly in mood regulation.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-01238APA
Ostadhadi, Sattar; Haj-Mirzaian, Arya; Nikoui, Vahid; Kordjazy, Nastaran; Dehpour, Ahmad-Reza. (2016). Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice.. Clinical and experimental pharmacology & physiology, 43(2), 203-12. https://doi.org/10.1111/1440-1681.12518
MLA
Ostadhadi, Sattar, et al. "Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice.." Clinical and experimental pharmacology & physiology, 2016. https://doi.org/10.1111/1440-1681.12518
RethinkTHC
RethinkTHC Research Database. "Involvement of opioid system in antidepressant-like effect o..." RTHC-01238. Retrieved from https://rethinkthc.com/research/ostadhadi-2016-involvement-of-opioid-system
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.